Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LRMR with free AI briefings, catalyst countdowns, and dilution alerts.

LRMR · Larimar Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 10.3 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Feb 26, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$128.7M Cash on Hand
10.3mo Cash Runway
15.7% Short Interest
$14.2 Analyst Target (10)
Follow LRMR by email Get an email when LRMR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LRMR, unsubscribe in one click. Privacy

📣 What LRMR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nomlabofusp Friedreich Ataxia Phase 3 · NCT07778836 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LRMR holds $128.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $37.6M/quarter from operations, an estimated runway of 10.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 77 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LRMR files for a raise →

👥 Who Owns LRMR

Insiders 35.8% Institutions (207 holders) 64.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
Deerfield Management Company, L.P. Institution (13G, 5%+) 35,667,474 34.09% 2026-02-27
James E Flynn
Director, 10% owner · +93,150 options
Insider 35,606,974 34.03% 2026-02-27
Blue Owl Capital Holdings LP Institution (13G, 5%+) 10,739,492 10.26% 2026-03-31
RTW Investments, LP Institution (13G, 5%+) 5,820,891 5.56% 2026-09-30
Blackrock Inc. Institution (13F) 5,770,174 5.51% 2026-09-30
Defilade Capital Management, L.P. Institution (13F) 4,934,439 4.72% 2026-09-30
Driehaus Capital Management, LLC Institution (13F) 3,128,669 2.99% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 2,974,901 2.84% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 2,971,385 2.84% 2026-09-30
AQR Capital Management, LLC Institution (13F) 2,240,623 2.14% 2026-09-30
Marshall Wace LLP Institution (13F) 2,195,954 2.10% 2026-09-30
Thomas Edward Hamilton
Director · +93,150 options
Insider 944,231 0.90% 2026-11-12

Share count 104,634,619 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-16
filed 2026-11-16
SHERMAN JEFFREY W
Purchase (P) 3,289 $3.06 8,289
2026-11-12
filed 2026-11-12
Hamilton Thomas Edward
Purchase (P) 70,000 $2.67 70,000
2026-11-11
filed 2026-11-12
THOMAS FRANK E
Purchase (P) 8,000 $2.73 15,000
2026-11-11
filed 2026-11-12
Shankar Gopi
Purchase (P) 5,000 $2.71 81,443
2026-11-11
filed 2026-11-12
Celano Michael
Purchase (P) 18,460 $2.71 234,245

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full LRMR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LRMR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.